IL237730B - Treatment of mild and moderate alzheimer's disease - Google Patents
Treatment of mild and moderate alzheimer's diseaseInfo
- Publication number
- IL237730B IL237730B IL237730A IL23773015A IL237730B IL 237730 B IL237730 B IL 237730B IL 237730 A IL237730 A IL 237730A IL 23773015 A IL23773015 A IL 23773015A IL 237730 B IL237730 B IL 237730B
- Authority
- IL
- Israel
- Prior art keywords
- mild
- disease
- treatment
- moderate alzheimer
- alzheimer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261710229P | 2012-10-05 | 2012-10-05 | |
| PCT/US2013/062964 WO2014055588A1 (en) | 2012-10-05 | 2013-10-02 | Treatment of mild and moderate alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL237730B true IL237730B (en) | 2018-10-31 |
Family
ID=49354960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL237730A IL237730B (en) | 2012-10-05 | 2015-03-12 | Treatment of mild and moderate alzheimer's disease |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9717710B2 (enExample) |
| EP (1) | EP2903606A1 (enExample) |
| JP (2) | JP6566868B2 (enExample) |
| KR (1) | KR20150064743A (enExample) |
| CN (2) | CN104703592A (enExample) |
| AU (2) | AU2013327450B2 (enExample) |
| BR (1) | BR112015007641A8 (enExample) |
| CA (1) | CA2886785C (enExample) |
| EA (1) | EA201590687A1 (enExample) |
| HK (1) | HK1207004A1 (enExample) |
| IL (1) | IL237730B (enExample) |
| IN (1) | IN2015DN03734A (enExample) |
| MX (1) | MX377733B (enExample) |
| NZ (2) | NZ705813A (enExample) |
| SG (2) | SG11201502210VA (enExample) |
| WO (1) | WO2014055588A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2019190823A1 (en) * | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| JP7464591B2 (ja) | 2018-10-10 | 2024-04-09 | ブイティーブイ・セラピューティクス・エルエルシー | ［３－（４－｛２－ブチル－１－［４－（４－クロロ－フェノキシ）－フェニル］－１ｈ－イミダゾール－４－イル｝－フェノキシ）－プロピル］－ジエチル－アミンの代謝産物 |
| WO2020086388A1 (en) * | 2018-10-22 | 2020-04-30 | Vtv Therapeutics Llc | Glucokinase activator compositions for the treatment of cognitive impairment |
| JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
| CN114957470B (zh) * | 2021-11-12 | 2023-01-17 | 深圳市人民医院 | 靶向rage的纳米抗体及其应用 |
| US11648235B1 (en) | 2022-12-30 | 2023-05-16 | Cantex Pharmaceuticals, Inc. | Treatment of glioblastoma |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585344A (en) | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
| EP0352581A3 (de) | 1988-07-28 | 1990-07-04 | F. Hoffmann-La Roche Ag | Aethylendiaminmonoamid-Derivate |
| US5166214A (en) | 1988-12-05 | 1992-11-24 | Du Pont Merck Pharmaceutical Company | Use of imidazoles for the treatment of atherosclerosis |
| US5840294A (en) | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| ES2170104T3 (es) | 1993-10-01 | 2002-08-01 | Merrell Pharma Inc | Inhibidores de la produccion de proteinas de beta-amiloide. |
| US5817626A (en) | 1995-03-14 | 1998-10-06 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation |
| US5939526A (en) | 1995-03-21 | 1999-08-17 | Ludwig Institute For Cancer Research | Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof |
| WO1997026913A1 (en) | 1996-01-26 | 1997-07-31 | The Trustees Of Columbia University In The City Of New York | A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE |
| US5864018A (en) | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
| WO1997039121A1 (en) | 1996-04-16 | 1997-10-23 | Schering Aktiengesellschaft | Advanced glycosylation end-product receptor peptides and uses therefor |
| EP1184370B1 (en) | 1996-07-22 | 2005-09-14 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| US6790443B2 (en) | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
| US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
| US6555651B2 (en) | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
| US5962535A (en) | 1997-01-17 | 1999-10-05 | Takeda Chemical Industries, Ltd. | Composition for alzheimer's disease |
| US6268479B1 (en) | 1997-03-12 | 2001-07-31 | The Trustees Of Columbia University In The City Of New York | Intracellular amyloid-beta peptide binding (ERAB) polypeptide |
| US7101838B2 (en) | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
| US6323218B1 (en) | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
| US6274615B1 (en) | 1998-03-25 | 2001-08-14 | South Alabama Medical Science Foundation | Method for delaying the onset of alheimer's disease and for treatment or delaying the onset of other amyloidosis-related diseases/disorders |
| US6465422B1 (en) | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
| US5981168A (en) | 1998-05-15 | 1999-11-09 | The University Of British Columbia | Method and composition for modulating amyloidosis |
| AU765142B2 (en) | 1998-06-01 | 2003-09-11 | Ortho-Mcneil Pharmaceutical, Inc. | Method for treating neurodegenerative disorders |
| AU1199600A (en) | 1998-10-02 | 2000-04-26 | Board Of Trustees Of The University Of Illinois, The | Estrogen receptor ligands |
| US6753150B2 (en) | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
| AU765719B2 (en) | 1998-10-06 | 2003-09-25 | Trustees Of Columbia University In The City Of New York, The | Extracellular novel rage binding protein (EN-RAGE) and uses thereof |
| JP2003507013A (ja) | 1999-08-13 | 2003-02-25 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | βシートフィブリルのＲＡＧＥへの結合を阻害する方法及びその結果 |
| US20010051642A1 (en) | 2000-04-17 | 2001-12-13 | Kyunghye Ahn | Method for treating Alzheimer's disease |
| US6613801B2 (en) | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
| US6825164B1 (en) | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
| CA2440042C (en) | 2001-03-05 | 2011-09-27 | Transtech Pharma, Inc. | Carboxamide derivatives as therapeutic agents |
| CN1235583C (zh) | 2001-03-05 | 2006-01-11 | 特兰斯泰克制药公司 | 用作治疗剂的苯并咪唑衍生物 |
| EP1482931B1 (en) | 2002-03-05 | 2011-10-19 | TransTech Pharma, Inc. | Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
| JP2006522128A (ja) | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−５のモジュレーターとしての４環イミダゾール誘導体 |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| CN1805743A (zh) * | 2003-05-20 | 2006-07-19 | 特兰斯泰克制药公司 | 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂 |
| SI1703902T1 (sl) | 2004-01-05 | 2011-02-28 | Merz Pharma Gmbh & Co Kgaa | Memantin za zdravljenje blage do zmerne Alzheimerjeve bolezni |
| DE102004050176A1 (de) | 2004-09-20 | 2006-03-23 | Universität Duisburg-Essen | Optoelektronisches Bauelement und Verfahren zum Steuern von Tunnelelektronenströmen durch Photonen |
| US7601745B2 (en) | 2004-09-27 | 2009-10-13 | 4Sc Ag | Heterocyclic NF-kB inhibitors |
| US20070135437A1 (en) | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
| EP1707203A1 (en) * | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands |
| WO2006124897A2 (en) | 2005-05-13 | 2006-11-23 | Lexicon Genetics Incorporated | Methods and compositions for improving cognition |
| US20080153811A1 (en) | 2006-11-07 | 2008-06-26 | Joseph Barbosa | Methods of Treating Cognitive Impairment and Dementia |
| CN101663280A (zh) * | 2007-04-05 | 2010-03-03 | 转化技术制药公司 | [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ |
| JP2010523559A (ja) * | 2007-04-05 | 2010-07-15 | トランス テック ファーマ，インコーポレイテッド | ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態 |
| US20100254983A1 (en) * | 2007-06-07 | 2010-10-07 | Ann Marie Schmidt | Uses of rage antagonists for treating obesity and related diseases |
| US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
| BRPI1012697A2 (pt) | 2009-04-27 | 2016-03-29 | High Point Pharmaceuticals Llc | derivados imidazo[1,2-a]piridina substituídos, composições farmacêuticas, e métodos de uso como inibidores da b-secretase |
| CA2772797C (en) | 2009-09-30 | 2018-09-25 | Transtech Pharma, Inc. | Substituted imidazole derivatives |
| TWI510241B (zh) | 2010-02-18 | 2015-12-01 | Vtv Therapeutice Llc | 苯基－雜芳基衍生物及其使用方法 |
| WO2012061927A1 (en) * | 2010-11-08 | 2012-05-18 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
-
2013
- 2013-10-02 KR KR1020157011366A patent/KR20150064743A/ko not_active Ceased
- 2013-10-02 SG SG11201502210VA patent/SG11201502210VA/en unknown
- 2013-10-02 EA EA201590687A patent/EA201590687A1/ru unknown
- 2013-10-02 MX MX2015003732A patent/MX377733B/es active IP Right Grant
- 2013-10-02 AU AU2013327450A patent/AU2013327450B2/en active Active
- 2013-10-02 NZ NZ705813A patent/NZ705813A/en unknown
- 2013-10-02 CN CN201380051206.0A patent/CN104703592A/zh active Pending
- 2013-10-02 CA CA2886785A patent/CA2886785C/en active Active
- 2013-10-02 CN CN201910466681.3A patent/CN110292638A/zh active Pending
- 2013-10-02 IN IN3734DEN2015 patent/IN2015DN03734A/en unknown
- 2013-10-02 WO PCT/US2013/062964 patent/WO2014055588A1/en not_active Ceased
- 2013-10-02 JP JP2015535750A patent/JP6566868B2/ja active Active
- 2013-10-02 BR BR112015007641A patent/BR112015007641A8/pt active Search and Examination
- 2013-10-02 EP EP13776676.2A patent/EP2903606A1/en not_active Withdrawn
- 2013-10-02 HK HK15107776.8A patent/HK1207004A1/xx unknown
- 2013-10-02 NZ NZ739521A patent/NZ739521A/en unknown
- 2013-10-02 SG SG10201702648YA patent/SG10201702648YA/en unknown
- 2013-10-22 US US14/059,529 patent/US9717710B2/en active Active
-
2015
- 2015-03-12 IL IL237730A patent/IL237730B/en active IP Right Grant
-
2017
- 2017-06-23 US US15/631,203 patent/US20170326113A1/en not_active Abandoned
-
2018
- 2018-05-16 AU AU2018203434A patent/AU2018203434A1/en not_active Abandoned
-
2019
- 2019-01-08 US US16/242,757 patent/US20190142803A1/en not_active Abandoned
- 2019-05-23 JP JP2019096786A patent/JP6894940B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170326113A1 (en) | 2017-11-16 |
| CN104703592A (zh) | 2015-06-10 |
| CA2886785C (en) | 2022-06-07 |
| MX2015003732A (es) | 2015-09-23 |
| MX377733B (es) | 2025-03-11 |
| JP2015535850A (ja) | 2015-12-17 |
| BR112015007641A8 (pt) | 2018-04-03 |
| CA2886785A1 (en) | 2014-04-10 |
| JP6566868B2 (ja) | 2019-08-28 |
| AU2013327450B2 (en) | 2018-07-12 |
| IN2015DN03734A (enExample) | 2015-09-18 |
| JP6894940B2 (ja) | 2021-06-30 |
| EP2903606A1 (en) | 2015-08-12 |
| BR112015007641A2 (pt) | 2017-07-04 |
| US20140100218A1 (en) | 2014-04-10 |
| US20190142803A1 (en) | 2019-05-16 |
| WO2014055588A1 (en) | 2014-04-10 |
| JP2019163301A (ja) | 2019-09-26 |
| AU2018203434A1 (en) | 2018-06-07 |
| CN110292638A (zh) | 2019-10-01 |
| KR20150064743A (ko) | 2015-06-11 |
| NZ739521A (en) | 2019-06-28 |
| AU2013327450A1 (en) | 2015-05-14 |
| NZ705813A (en) | 2018-02-23 |
| EA201590687A1 (ru) | 2015-09-30 |
| US9717710B2 (en) | 2017-08-01 |
| HK1207004A1 (en) | 2016-01-22 |
| SG11201502210VA (en) | 2015-04-29 |
| SG10201702648YA (en) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL237369A0 (en) | Methods for treating Alzheimer's disease and pharmaceutical compositions thereof | |
| IL266582A (en) | Preparations and methods for the treatment of hemoglobin diseases | |
| IL265774B (en) | Diagnosis, prevention and treatment of joint diseases | |
| EP2890440A4 (en) | DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES | |
| IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
| EP3261721A4 (en) | Use of pridopidine to improve cognitive function and for treating alzheimer's disease | |
| EP2707369A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | |
| IL225239A0 (en) | Compounds for the treatment of acne and related diseases | |
| PL2968218T3 (pl) | Skojarzenie do leczenia choroby parkinsona | |
| ZA201500561B (en) | Compositions and treatment for eye diseases and disorders | |
| ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
| SG11201403272YA (en) | Compositions and methods for treating alzheimer's disease | |
| SG10201702648YA (en) | Treatment of mild and moderate alzheimer's disease | |
| HUS2000020I1 (hu) | Ciklezonid a légúti betegségek kezelésére lovaknál | |
| GB2515439B (en) | Vesicular formulations for use in the treatment of reduced mobility | |
| EP2709632A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES | |
| IL233572B (en) | A pharmaceutical preparation containing a mixture with fixed doses for the treatment of Parkinson's disease | |
| PL2892556T3 (pl) | Kompozycje i sposoby odnoszące się do leczenia chorób | |
| SG11201404649UA (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| ZA201408057B (en) | Compositions and methods for the treatment of moderate to severe pain | |
| ZA201402477B (en) | Compounds for use in the treatment of alzheimer's disease | |
| EP2934501A4 (en) | USES AND METHOD FOR THE TREATMENT OF LIVER DISEASES OR DRESSES | |
| PL2565184T3 (pl) | Środek terapeutyczny i środek zapobiegawczy przeciwko chorobie alzheimera | |
| HK1183408A (en) | Treatment of mci and alzheimer's disease | |
| GB201101088D0 (en) | L-carnosine and cinnamon extract for the treatment of Alzheimer's Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |